MindMed Medicine Inc. (NASDAQ: MNMD) has announced a collaboration with Florian Inc. (NASDAQ: FORA) for comprehensive commercial and clinical decision making.
MindMed and Florian collaborate
The companies will work together to create best practices to leverage real-world evidence data to help psychiatric patients better their health and lifestyles. Forian has extensive domain expertise in RWE and outcomes trials and has created several healthcare-related information solutions. Notably, large, real-world health databases facilitate finding and connections that might otherwise be missed in episodic health visits. In addition, when many visits are observed in a representative group, patterns emerge.
MindMed Chief Medical Officer Dan Karlin said, “Our goal is to use real-world healthcare data and deep digital phenotyping to achieve in-depth, precise and personalized characterizations of individuals with generalized anxiety disorders and other conditions of interest for our drug development programs. By fully acknowledging each person’s physiology, environment, and behavioral stressors, we ultimately aim for integrated digital deep diagnoses to drive precision psychiatry for drug development and clinical treatment across our target therapeutic areas.”
Florian CEO Dan Barton said, “Forian understands the power our real-world evidence and unique data sets add to our healthcare and pharmaceutical partners. We are thrilled to collaborate with MindMed to help them deliver insights to improve the health of psychiatric patients.”
Pandemic impact highlighting the need for customized solutions
The global pandemic’s devastating mental health consequences highlight the need for customized solutions and therapies that can be delivered in a proactive instead of reactionary way. MindMed is utilizing recent advancements in multi-omics, real-world information, and artificial intelligence to assist in developing comprehensive and individualized psychiatry solutions.
MindMed is putting together a compelling drug development pipeline of cutting-edge medicines based on psychedelic chemicals like psilocybin, MDMA, LSD, DMT, and 18-MC, an Ibogaine derivative. The MindMed management team’s approach to producing the next generation of psychedelic-inspired medications and therapies is informed by considerable biopharmaceutical experience.
